1. Home
  2. CAPT vs COCP Comparison

CAPT vs COCP Comparison

Compare CAPT & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAPT

Captivision Inc.

N/A

Current Price

$0.43

Market Cap

13.2M

Sector

Finance

ML Signal

N/A

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

N/A

Current Price

$1.07

Market Cap

15.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPT
COCP
Founded
2005
2006
Country
South Korea
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
15.3M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
CAPT
COCP
Price
$0.43
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
254.7K
33.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
8.02
EPS
N/A
N/A
Revenue
N/A
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$0.86
52 Week High
$1.93
$2.19

Technical Indicators

Market Signals
Indicator
CAPT
COCP
Relative Strength Index (RSI) 44.94 57.70
Support Level $0.39 $1.01
Resistance Level $0.58 $1.11
Average True Range (ATR) 0.02 0.06
MACD 0.00 0.01
Stochastic Oscillator 56.74 72.27

Price Performance

Historical Comparison
CAPT
COCP

About CAPT Captivision Inc.

Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Share on Social Networks: